Market Wrap Week 28: Caspin Surges, Cobre Slides, Genesis Keeps Gold Deals Alive

Caspin Resources (ASX:CPN) led the week with a 49.35% jump after it reported its best tin intercept yet at the Kelpie Deposit, including 20 metres at 2.11% tin. Investors cared because the result sits outside the current resource and could make the deposit bigger. Southern Palladium (ASX:SPD) climbed 27.57% after test work lifted chromite recovery from 30% to 85.6%, which matters because better recovery means more saleable product from the same rock. On the downside, Cobre (ASX:CBE) fell 27.40% after announcing a A$90 million placement at a discount, a result that often worries holders because new shares can dilute existing investors.

Gold deals and drilling stayed front and centre

Genesis Minerals (ASX:GMD) set the tone in large-cap gold with its A$5.6 billion move on Vault Minerals (ASX:VAU). The offer topped the existing Regis Resources proposal and won unanimous backing from the Vault board. Vault finished the week up 6.80%, but some early excitement faded after trading resumed, which suggests traders are now waiting to see if Regis responds. Genesis fell 9.86%, a common reaction when the bidder is expected to issue shares and absorb integration work.

Elsewhere in gold, drill-driven names kept screens busy. Meteoric Resources (ASX:MEI) rose 12.50% after a big jump in measured rare earth resources, but many gold juniors struggled to hold early pops. Southern Cross Gold (ASX:SX2) slipped 3.11% even after strong antimony-rich assays at Sunday Creek, while Torque Metals (ASX:TOR) lost 8.00% despite a 67% resource increase at Paris. In simple terms, good drill news was not always enough if traders had already bought in earlier or wanted quicker progress towards mining.

Capital raisings split the market

Fresh money helped some companies and hurt others. SPC Global (ASX:SPG) gained 4.17% after reporting solid sales growth and cutting debt with a A$100 million equity raising. Investors liked that the balance sheet is now less stretched, which means less pressure from borrowings. Carbonxt (ASX:CG1) added 17.65% as its recapitalisation cut debt and gave its Kentucky plant more time to ramp up.

By contrast, some discounted placements were treated as a warning sign. Minerals 260 (ASX:MI6) dropped 18.42% even though its Bullabulling study showed strong project economics. The stock reopened and then sank further, which tells you early buyers stepped away and sellers stayed in control. Brazilian Critical Minerals (ASX:BCM) fell 5.45% after a A$10 million placement, while Imugene (ASX:IMU) slid 22.22% despite raising cash for its cell therapy program. In both cases, investors seemed more focused on dilution and cash burn than on the story attached to the raise.

Critical minerals and base metals kept producing big swings

Rare earths, manganese, tungsten and copper names delivered a long list of updates. Element 25 (ASX:E25) rose 11.11% after securing a US$166 million US Department of Energy grant for its Louisiana battery materials plant. That matters because government money reduces the amount shareholders may need to contribute. Viridis Mining (ASX:VMM) fell 13.37% even after upgrading its Colossus resource, showing that financing milestones are helpful but do not always produce instant buying.

Copper names were mixed. Finder Energy (ASX:FDR) climbed 19.30% on offshore oil approvals rather than copper, but the broader resources trade also backed names with near-term development steps such as Anax Metals (ASX:ANX), up 10.71%, and TechGen Metals (ASX:TG1), up 10.00%. Waratah Minerals (ASX:WTM) fell 16.36% after buying the Ironclad lease, which suggests investors wanted to see drilling results rather than another asset added to the portfolio.

Outside mining, contracts and approvals mattered

Several non-resources names put up strong numbers on concrete business updates. X2M Connect (ASX:X2M) rose 20.00% after winning a A$1.1 million Seoul contract and extending its device rollout. Buyers stuck with the stock after it resumed, which points to sustained demand rather than a short-lived spike. Island Pharmaceuticals (ASX:ILA) also gained 20.00% as its antiviral program won government approvals tied to Ebola response work, though some of the early surge later eased.

Nine Entertainment (ASX:NEC) added 3.28% after locking in long-term NRL and NRLW rights, a deal investors value because sport can hold viewers and advertising revenue. ResMed (ASX:RMD) was steadier, down 1.54%, after selling MatrixCare for US$490 million. The sale gives it cash for buybacks and product spending, but the market now wants detail on how that money will be used in fiscal 2027.

What the tape said this week

The clearest pattern was simple. Stocks with a direct event that could change cash flow soon, such as stronger recoveries, large grants, signed contracts or a live takeover, attracted firmer buying. Stocks that asked investors for more capital often fell, even when the project update itself looked strong. A second pattern was that many gap opens did not hold. Early gains evaporated in several names once the first burst of trading passed, while a smaller group kept climbing after the reopen. That split tells you traders were demanding near-term proof, not just promising headline numbers.